EUVIMEDEUVIMED entdecken
Crossref

One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals

Qian Guo, Chuanke Zhao, Xiangyu Gao, Lixin Ding, Pei Wang, Ya'nan Ren, Xingguo Hou, Yuan Yao, Cheng Zhang, Xianteng Yang, Zhi Yang, Hua Zhu

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Qian Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, Guizhou University, Guiyang 550025, China. Hauptthemen laut MEDLINE: Iodine, Prostatic Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Digestive Medical Coordinated Development Center of Beijing Hospitals Authority, National Natural Science Foundation of China, Beijing Hospitals Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real-time monitoring of the biological behavior of extracellular vesicles (EVs) in vivo is limited, which hinders its application in biomedicine and clinical translation. A noninvasive imaging strategy could provide us with useful information on EVs' distribution, accumulation and homing in vivo, and pharmacokinetics. In this study, the long half-life radionuclide iodine-124 (124I) was used to directly label umbilical cord mesenchymal stem cell-derived EVs. The resulting probe, namely, 124I-MSC-EVs, was manufactured and ready to use within 1 min. 124I-labeled MSC-EVs had high radiochemical purity (RCP, >99.4%) and stable in 5% human serum album (HSA) with RCP > 95% for 96 h. We demonstrated efficient intracellular internalization of 124I-MSC-EVs in two prostate cancer cell lines (22RV1 and DU145 cell). The uptake rates of 124I-MSC-EVs in human prostate cancer cell lines 22RV1 and DU145 cells were 10.35 ± 0.78 and 2.56 ± 0.21 (AD%) at 4 h. The promising cellular data has prompted us to investigate the biodistribution and in vivo tracking capability of this isotope-based labeling technique in tumor bearing animals. Using positron emission tomography (PET) technology, we showed that the signal from intravenously injected 124I-MSC-EVs mainly accumulated in the heart, liver, spleen, lung, and kidney in healthy kun ming (KM) mice, and the biodistribution study was similar to the imaging results. In the 22RV1 xenograft model, 124I-MSC-EVs accumulated significantly in the tumor after administration, and with the optimal image acquired at 48 h postinjection, the maximum of standard uptake value (SUVmax) of the tumor was 3-fold higher than that of DU145. Taken together, the probe has a high application prospect in immuno-PET imaging of EVs. Our technique provides a powerful and convenient tool for understanding the biological behavior and pharmacokinetic characteristics of EVs in vivo and facilitates the acquirement of comprehensive and objective data for future clinical studies of EVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IodineProstatic NeoplasmsExtracellular VesiclesMaleHumansAnimalsMiceTissue DistributionIsotope LabelingIodine Radioisotopes

Stichwörter der Autor:innen

Extracellular vesiclesexosomesiodine isotopemolecular imagingradiopharmaceutical

Substanzen

IodineIodine-124Iodine Radioisotopes

Autor:innen und Institutionen

  • Medical College, Guizhou University, Guiyang 550025, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Department of Orthopaedics, Guizhou Provincial People's Hospital, Guiyang 550002, China.

Förderung

  • Digestive Medical Coordinated Development Center of Beijing Hospitals Authority
  • National Natural Science Foundation of China
  • Beijing Hospitals Authority
  • Pilot Project (4th Round) to Reform Public Development of Beijing Municipal Medical Research Institute

Zitieren

APA

Guo, Q., Zhao, C., Gao, X., Ding, L., Wang, P., Ren, Y., Hou, X., Yao, Y., Zhang, C., Yang, X., Yang, Z., & Zhu, H. (2023). One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00299

Vancouver

Guo Q, Zhao C, Gao X, Ding L, Wang P, Ren Y, et al. One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00299

BibTeX
@article{Guo2023,
  author = {Guo, Qian and Zhao, Chuanke and Gao, Xiangyu and Ding, Lixin and Wang, Pei and Ren, Ya'nan and Hou, Xingguo and Yao, Yuan and Zhang, Cheng and Yang, Xianteng and Yang, Zhi and Zhu, Hua},
  title = {One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00299}
}
Kostenlos starten →